Search
Frovatriptan
go.drugbank.com/drugs/DB00998ApprovedFrovatriptan is a triptan drug developed by Vernalis for the treatment of migraine headaches, in particular those associated with menstruation.
Rurioctocog alfa pegol
go.drugbank.com/drugs/DB16007ApprovedInvestigationalIt was first approved by the European Commission in January 2018. … [A245149] Hemophilia A is the most common inherited bleeding disorder leading to deficiency of factor VIII, which is caused by defects in the F8C gene that encodes coagulation factor VIII.
Calfactant
go.drugbank.com/drugs/DB06415ApprovedInvestigationalCalfactant is a sterile, non-pyrogenic lung surfactant intended for intratracheal instillation. It is an off-white suspension of an extract of natural surfactant from calf lungs suspended in 0.9% saline. Each milliliter of calfactant con...
Trabectedin
go.drugbank.com/drugs/DB05109ApprovedInvestigationalTrabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate Ecteinascidia turbinata and now produced synthetically. Trabectedin has a unique mechanism of action. I...
Droperidol
go.drugbank.com/drugs/DB00450ApprovedInvestigationalVet approvedIt is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the
Resmetirom
go.drugbank.com/drugs/DB12914ApprovedInvestigational[A263461] Resmetirom works to reduce liver fat by stimulating fatty acid degradation and oxidation.[L50336] … On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD
Fulvestrant
go.drugbank.com/drugs/DB00947ApprovedInvestigationalIt is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor.
Lapatinib
go.drugbank.com/drugs/DB01259ApprovedInvestigationalLapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. … It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine.
Edetic acid
go.drugbank.com/drugs/DB00974ApprovedInvestigationalVet approvedA chelating agent (chelating agents) that sequesters a variety of polyvalent cations. It is used in pharmaceutical manufacturing and as a food additive.
Selinexor
go.drugbank.com/drugs/DB11942ApprovedInvestigational[L7117,L7120,L10145] This condition is typically treated with high dose [bortezomib] and [dexamethasone] chemotherapy followed by an autologous stem-cell transplant. … [L10145] The use of selinexor in combination with [bortezomib] and [dexamethasone] was approved by Health Canada in June 2022 for the treatment of multiple myeloma in adult patients who have received at